Answers are grounded in this paper and cite their sources.
Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer-related deaths among women globally.Despite advances in targeted therapies, such as trastuzumab emtansine (T-DM1), human epidermal receptor 2 (HER2)-positive metastatic breast cancer (mBC) remains challenging to treat, requiring prolonged therapy and substantial financial burdens.This study aimed to estimate non-pharmaceutical medical costs during third-line and fourth-line of therapies for HER2-positive mBC in South Korea.This population-based study utilized data from the Health Insurance Review and Assessment Service database (2009)(2010)(2011)(2012)(2013)(2014)(2015)(2016)(2017)(2018)(2019)(2020)(2021).Patients with HER2-positive mBC were identified using the ICD-10 code (breast cancer, C50; metastasis, C77, C78, C79) and a history of T-DM1 use to confirm HER2 positivity.Third-line therapy was defined as the prescription of lapatinib and capecitabine combination therapy, while fourth-line therapy comprised various combination regimens.From August 2017 to August 2020, 223 patients received third-line therapy.Non-pharmaceutical medical costs per patient were $1,579 for third-line therapy and $1,793 for subsequent therapies per treatment cycle.Costs increased under fourth-line therapy, reflecting the greater resource utilization associated with advanced disease.This study underscores the significant economic burden of advanced HER2-positive mBC, highlighting the need for innovative therapeutics to delay disease progression and reduce healthcare costs.The findings highlight the need for evidence-based policy measures and efficient healthcare resource allocation to address economic challenges while striving to enhance patient outcomes.
No takes yet. Share an insight, caveat, or question.
Jang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: